Listed

XBiotech Inc.: Form 10-K for the period ended Dec 31, 2016

Filed with the SEC on Mar 16, 2017 and accepted by EDGAR at Mar 16, 2017, 16:11 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2016-01-01 to 2016-12-31$42.5mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2016-01-01 to 2016-12-31−$52.8mus-gaap:OperatingIncomeLoss
Income tax12 months2016-01-01 to 2016-12-31$0us-gaap:IncomeTaxExpenseBenefit
Net income12 months2016-01-01 to 2016-12-31−$50.7mus-gaap:NetIncomeLoss
Diluted EPS12 months2016-01-01 to 2016-12-31−$1.63us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2016-01-01 to 2016-12-31−$46.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2016-01-01 to 2016-12-31$4.7mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2016-12-31$34.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-12-31$36.9mus-gaap:AssetsCurrent
Total assetsAt period end2016-12-31$67.0mus-gaap:Assets
Current liabilitiesAt period end2016-12-31$8.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-12-31$8.0mus-gaap:Liabilities
Shareholders' equityAt period end2016-12-31$59.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001171843-17-001571. Last ingested by Listed: Nov 14, 2026, 18:14 ET. Listed shows no prices and gives no investment advice.